ENTERA BIO LTD. Other Noncash Income (Expense)
ENTERA BIO LTD. (ENTX) reported Other Noncash Income (Expense) of -$2.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-07
- 2026-06-30: Other Noncash Income (Expense) 6 month -$2.75M.
- 2025-06-30: Other Noncash Income (Expense) 6 month $0.00.
| Period end | Other Noncash Income (Expense) 6 month |
|---|---|
| 2026-06-30 | -$2.75M 10-Q · filed 2026-08-07 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |